Juridical Foundation, Japanese Foundation for Cancer Research

Ajinomoto Co., Ltd.

Boehringer Ingelheim International Gmbh

Other

Japanese Foundation for Cancer Research

New York University

Japan Science and Technology Agency

The University of Tokyo

Kyowa Hakko Kogyo Co., Ltd.

Tadatsugu Taniguchi

Boostimmune, Inc.

Haruo Sugano

Masami Muramatsu

Hiroshi Matsui

Nobukazu Kashima

Junji Hamuro

Takashi Fujita

Tatsunari Nishi

Seiga Itoh

Takeshi Kono

Sejiro Minamoto

Takeshi Doi

Masayuki Miyasaka

Mitsuru Tsudo

Masanori Hatakeyama

Jan T Vilcek

Susumu Sekine

Tadashi Matsumoto

Tamio Mizukami

Tetsuo Oka

Edward Leon Barsoumian

Hideyuki Yanai

Mitsuaki Yoshida

Yum K Yip

Hajime Karasuyama

Gwanghee Lee

Sho Hangai

Hajime Karasuyma

Hiroshi Shibuya

Hisashi Harada

Shigeo Ono

Jiwon Huh

Jeonghyun Ryou

Yanai Hideyuki

The present invention relates to a novel combination of (1) a substance that suppresses or inhibits the function of extracellular TCTP (translationally controlled tumor protein), especially released from tumor cells, and (2) a cancer immunotherapeutic agent for the treatment of cancer. Preferably, such a cancer immunotherapeutic agent is an immune checkpoint inhibitor. The substance that suppresses or inhibits the function of extracellular TCTP functions as an activator or enhancer of anti-tumor immune cells including T cells and natural killer (NK) cells and/or an antagonist of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs), in the tumor immune microenvironment (TIME). The combination according to the present invention is useful for treating or preventing cancer. The combination according to the present invention is also useful for alleviating, reverting, or preventing immune suppression in the tumor immune microenvironment.

Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer

Disclosed is a recombinant plasmid having a gene which encompasses at least the entire coding region of human fibroblast interferon messenger RNA and a method for preparing such plasmid.

DNA and recombinant plasmid

Provided are an inhibitor of activation of an immune response mediated by an HMGB protein, the inhibitor containing at least one compound selected from the group consisting of a phosphorothioate oligonucleotide and a derivative thereof, and a method of screening for an inhibitor or enhancer of activation of an immune response mediated by an HMGB protein.

Inhibitor of HMGB protein-mediated immune response activation, and screening method

The present invention relates to a polypeptide, p,, which is associated with the interleukin-,receptor (IL-,R). It binds specifically to the &bgr; and &ggr; subunits of IL-,R and is further capable of binding NAD,. The invention is further related to nucleic acid molecules coding for p,and to antibodies specifically binding to p

IL-2R-associated polypeptide and DNA molecules coding therefor

A recombinant DNA molecule coding for a protein having the activity of an interferon regulatory factor-1 (IRF-1).

Factor regulating gene expression

A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is trans-formed to produce interleukin-2.

Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the

A gene coded for a polypeptide which possesses interleukin-2 is isolated, and connected with a vector DNA which is capable of replicating in a procaryotic or eucaryotic cell at a position downstream of a promoter gene in the vector obtaining a recombinant DNA, with which the cell is transformed to produce interleukin-2.

Gene encoding interleukin-2 polypeptide, recombinant DNA carrying the

A method of producing a recombinant protein having the activity of an interferon regulatory factor-1 (IRF-1) or a target protein, are described.

Coding, promoter and regulator sequences of IRF-1

A plasmid containing a recombinant DNA molecule coding for a protein having the activity of an interferon regulatory factor-1 (IRF-1) and promoter and regulator sequences thereof, are described.

Recombinant human Interleukin-2 (IL-2) polypeptides are provided. The polypeptides are produced by expression of suitable nucleic acid molecules in transformed host cells such as E. coli.

Unglycosylated human interleukin-2 polypeptides

The present invention relates to a method of altering the phenotype of cells expressing an oncogene by expressing a nucleic acid encoding interferon regulatory factor 1 (IRF-1).

IRF-1 DNA expression inhibits growth of cells expressing c-myc or FosB

The present invention concerns a novel molecular marker useful for diagnosing hematopoietic disorders, including cancers and precancerous conditions. The invention is based on the unexpected discovery that inactivation of the IRF-1 tumor suppressor gene can occur via an altered splicing pattern of the IRF-1 primary transcript. This altered splicing pattern leads to mRNAs lacking exon 2 or exons 2 and 3. The relative amounts of full-length RNA and shortened RNA molecules are significantly different in samples obtained from patients suffering from certain cancers and precancerous conditions as compared to healthy donors.

Methods for diagnosing cancer, precancerous state, or susceptibility to

Growing community of inventors

Tokyo, Japan

Tadatsugu Taniguchi